What ChondroFiller is — and which hip patients it suits

A localised area where the smooth lining of the hip joint has worn away or been damaged — rather than widespread joint degeneration — is the starting point for considering ChondroFiller™. If you have been told you have a focal cartilage defect in your hip, this is the kind of finding this treatment is designed for.

ChondroFiller™, also marketed as Liquid Cartilage™, is a CE-marked Class III medical device: an acellular injectable collagen scaffold. It is neither a lubricant injection (such as hyaluronic acid) nor an anti-inflammatory one (such as a corticosteroid). Its role is to provide a structural framework that supports the body's own repair processes within a defined cartilage lesion.

The most common hip presentation suited to ChondroFiller™ is anterosuperior acetabular cartilage damage linked to femoroacetabular impingement (FAI) — particularly cam-type FAI, where an abnormally shaped femoral head gradually damages the acetabular lining in active or younger patients. Defects of approximately 2–6 cm² with clear, vertical borders are the target lesion. Diffuse or open-bordered damage is not suitable, because the injectable collagen disperses into the joint cavity before it can set, preventing scaffold formation.

General hip osteoarthritis affecting the whole joint surface is also outside the indication for this treatment.

Before any appointment is booked, an MRI of the hip is required. Imaging determines whether the defect is contained, establishes its size, and guides how many units of product will be needed — decisions that cannot be made without seeing the joint.

The two-chamber syringe and in-situ gelling

The engineering answer to 'how does a liquid stay in place' is built into the syringe itself.

ChondroFiller™ is supplied in a two-chamber delivery system. One chamber holds the liquid Type I collagen solution; the other holds a neutralising buffer. Critically, the two components are kept completely separate inside the syringe and only combine as they pass through a mixing adapter at the very tip of the needle — at the moment of injection, not before.

As the collagen solution and buffer meet, the buffer shifts the mixture's pH — the measure of acidity — from its stored acidic state to a physiological neutral level, the same pH found naturally inside the body's tissues. This pH shift triggers polymerisation: the process by which individual collagen molecules self-assemble into an interlocking network of fibres. Think of it loosely as the way a gel sets when conditions change around it — except here, it is the chemical environment of the joint itself that drives the transformation.

Within approximately 3–5 minutes, the material solidifies from a flowing liquid into a structured, sponge-like three-dimensional hydrogel inside the hip joint. Once set, it bonds directly to the surrounding native cartilage walls of the defect. No surgical preparation of the cartilage surface is needed beforehand — the scaffold anchors through the natural affinity between the injected collagen matrix and the host tissue.

The practical implication is straightforward: the product arrives as a liquid for ease of precise, image-guided delivery, but becomes a stable, anchored scaffold within the defect in the time it takes to complete the injection appointment.

Why ultrasound guidance is essential for the hip

Placing a product that gels within three to five minutes leaves no margin for imprecise delivery — and the anatomy of the hip makes precision particularly demanding.

The hip joint lies several centimetres below the skin, beneath the body's largest muscle groups. Unlike more superficial joints, it cannot be accessed reliably by feel alone. Research in orthopaedic injection practice indicates that up to 30% of injections into anatomically deep joints placed without image guidance fail to land intralesionally — meaning the material enters the general joint cavity rather than the specific defect site. For most injectable therapies, landing somewhere inside the joint is sufficient. For ChondroFiller™, it is not.

The gelling mechanism explained in the previous section depends entirely on spatial precision: the scaffold can only recruit repair cells and form a structured template where it physically occupies the defect. Collagen that disperses freely into the joint space before polymerising cannot organise itself into a functional matrix. Accurate placement inside the lesion itself — not merely inside the hip — is therefore a mechanical requirement of the treatment, not an optional refinement.

Real-time ultrasound addresses this directly. The clinician can visualise the needle tip advancing into the anterior recess of the hip joint and monitor the material filling the defect as the injection proceeds. This continuous imaging also allows the clinician to confirm the needle is clear of the femoral artery and adjacent neurovascular structures before placement begins — an important safety step given how close these vessels run to the injection site.

What the scaffold does after it sets: cell recruitment and repair

Once the collagen scaffold has set inside the defect, it contains no living cells of its own — and that is precisely the point.

The scaffold's role is to act as a chemotactic template: a structured three-dimensional matrix whose collagen architecture signals to the body that repair is needed and provides a physical framework for repair cells to enter and organise. Mesenchymal stem cells and chondrocyte precursors — progenitor cells already present in the hip's surrounding synovium and subchondral bone — migrate into the scaffold, guided by the collagen structure. Once inside, those recruited cells mature into chondrocytes, the specialised cartilage-producing cells, and begin depositing repair cartilage matrix. The clinical term for this sequence is matrix-induced chondrogenesis: cartilage repair driven by the patient's own cells, prompted by the scaffold rather than carried in by it.

Over subsequent months, the original collagen framework gradually biodegrades. As it does so, the patient's own repair tissue progressively replaces it, meaning what remains is endogenous material rather than a permanent implant. This biodegradation arc is central to understanding what ChondroFiller™ actually does: the scaffold is a temporary biological prompt, not a long-term foreign insert.

The distinction from other hip injections is mechanistic. Hyaluronic acid works by temporarily supplementing joint-fluid lubrication; corticosteroid reduces acute inflammation. Neither creates a physical template for cell recruitment nor promotes endogenous repair through the same pathway. ChondroFiller™ operates through a different biological route altogether — which is why it is positioned as a regenerative option rather than a palliative one.

Published clinical series spanning more than 19,000 cases across multiple joints report symptom relief in approximately 70–85% of patients. Those figures, however, come predominantly from a broad multi-joint evidence base; outcome data specific to the ultrasound-guided injectable route in the hip remain limited, and the evidence base continues to develop. The broader case-series figures should not be read as confirmed hip-specific outcomes.

The injection appointment and recovery timeline

The procedure itself takes place as a single outpatient appointment — no general anaesthetic, no theatre booking, no surgical incision of any kind.

On the day, local anaesthesia is administered to numb the skin and soft tissue overlying the hip. The clinician uses real-time ultrasound to guide the needle into the anterior recess of the joint — the same image-guided approach covered in the previous section. Once the needle is correctly positioned, the collagen material is delivered directly into the defect. In-situ gelling begins within the first few minutes; the injection itself is brief once the hip has been localised under ultrasound. You will also receive intravenous antibiotic cover during the procedure as standard.

Following the injection, a period of approximately six weeks of partial weight-bearing is standard. This protected phase allows the scaffold to stabilise within the defect and gives migrating progenitor cells the mechanical conditions they need to begin colonising the matrix — processes that early loading could disrupt. A clinical review is typically scheduled at around the six-week mark; follow-up imaging at that stage or later can assess how the scaffold has integrated with the surrounding native cartilage, giving the clinical team an objective measure of progress.

Light activity and structured rehabilitation generally begin once the protected weight-bearing phase is complete. Return to sport is expected at around twelve months — a timeline that reflects the biological pace of tissue repair rather than the duration of the procedure itself. Setting that expectation before you attend is an important part of preparation, and it is worth discussing your specific activity goals with the treating clinician at the outset.

Cost, NHS access, and how to find out if it suits your hip

ChondroFiller™ is not funded by the NHS and is not covered by most major UK private health insurers, including Bupa and AXA. The full cost falls to the patient.

Indicative all-inclusive pricing from specialist UK clinics ranges from approximately £3,000 for a single-box treatment to around £8,000 for three boxes. The number of boxes is determined by defect size established on pre-treatment MRI — no clinic can responsibly quote a price before seeing the imaging, since box count cannot be reliably estimated without it. All figures should be confirmed directly with the treating clinic, as costs vary by provider and by case complexity.

ChondroFiller™ is manufactured by Meidrix Biomedicals GmbH in Germany and imported specifically for each individual patient under prescription. It is not available through NHS dispensing or standard pharmacy supply channels.

Whether the treatment suits a particular hip depends on the cartilage defect's size, location, and containment — factors that a pre-treatment MRI and a clinical assessment must establish. Patients approaching an initial consultation are advised to bring any existing hip imaging and a summary of previous treatments; this allows the clinician to review defect suitability and determine appropriate product volumes before any treatment plan is discussed.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral for hip assessment, with clinics in Sleaford and Grantham.